- Home
- MDCX vs LSTA Comparison
MDCX vs LSTA Comparison
Compare MDCX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- LSTA
- Stock Information
- Founded
- MDCX 2008
- LSTA 1980
- Country
- MDCX United States
- LSTA United States
- Employees
- MDCX N/A
- LSTA N/A
- Industry
- MDCX
- LSTA Misc Health and Biotechnology Services
- Sector
- MDCX
- LSTA Health Care
- Exchange
- MDCX Nasdaq
- LSTA Nasdaq
- Market Cap
- MDCX 50.8M
- LSTA 20.9M
- IPO Year
- MDCX N/A
- LSTA N/A
- Fundamental
- Price
- MDCX $2.29
- LSTA $2.43
- Analyst Decision
- MDCX Strong Buy
- LSTA Strong Buy
- Analyst Count
- MDCX 2
- LSTA 2
- Target Price
- MDCX $23.50
- LSTA $23.50
- AVG Volume (30 Days)
- MDCX 402.4K
- LSTA 41.2K
- Earning Date
- MDCX 11-22-2025
- LSTA 11-11-2025
- Dividend Yield
- MDCX N/A
- LSTA N/A
- EPS Growth
- MDCX N/A
- LSTA N/A
- EPS
- MDCX N/A
- LSTA N/A
- Revenue
- MDCX N/A
- LSTA $1,070,000.00
- Revenue This Year
- MDCX N/A
- LSTA N/A
- Revenue Next Year
- MDCX N/A
- LSTA N/A
- P/E Ratio
- MDCX N/A
- LSTA N/A
- Revenue Growth
- MDCX N/A
- LSTA N/A
- 52 Week Low
- MDCX $1.79
- LSTA $1.87
- 52 Week High
- MDCX $8.94
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- MDCX 47.86
- LSTA 49.26
- Support Level
- MDCX $2.33
- LSTA $2.34
- Resistance Level
- MDCX $2.70
- LSTA $2.50
- Average True Range (ATR)
- MDCX 0.20
- LSTA 0.17
- MACD
- MDCX -0.02
- LSTA -0.00
- Stochastic Oscillator
- MDCX 32.67
- LSTA 45.95
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.